WHO Strategic Advisory Group of Experts (SAGE) on Immunization published a 2022 position paper on seasonal influenza vaccines, including “evidence to recommendation” tables.
Milestone
6.2.c
Summary of critical evidence
In progress
Similar to the “evidence to recommendation” framework created by the WHO Strategic Advisory Group of Experts on Immunizations Working Group on COVID-19 vaccines, create a framework that identifies the critical evidence needed to inform (1) the design of clinical trials for universal or broadly protective influenza vaccines and (2) policy recommendations for the use of universal or broadly protective influenza vaccines once they are approved.
Progress Highlights
Yang 2024 used modeling to evaluate vaccine formulation and strategies, based on host immunological history and the co-existence of groups 1 and 2 HA strains, and developed a vaccine population-level target product profile (PTPP) for influenza vaccines showing that a future vaccine providing sufficiently broad and long-lived cross-group protection at a sufficiently high vaccination rate could prevent pandemic emergence and lower the pandemic burden.